Expert review of cardiovascular therapy|2025|Kumar A et al.
PMID: 40946170
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
AIMS: This post hoc analysis assessed the efficacy and safety data in tirzepatide-treated Korean patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Data specifically from Korean patients treated with tirzepatide 5, 10, or 15 mg in the multic…
Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), play pivotal roles in glucose homeostasis and metabolic regulation. Therapeutic incretin receptor agonists (RAs), such as tirzepatide…
Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders. Despite the si…
INTRODUCTION: Tirzepatide, a dual GIP/GLP-1 receptor agonist, is highly effective in reducing body weight and improving glucometabolic outcomes. However, most clinical trials have overlooked the role of diet quality, leaving unclear whether lifestyle…
We appreciate the thoughtful commentary by Drs. Dziewierz and Siudak regarding our study comparing tirzepatide versus semaglutide in post-CABG diabetic patients. While we acknowledge the inherent limitations of observational research, our propensity…
Obstructive sleep apnea (OSA) is a prevalent global health issue, with recent advances in pharmacotherapy expanding treatment options. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has been newly approved by the FDA for managing moderate to sev…
About half of the world's population is living with overweight or obesity. Tirzepatide is an approved treatment for chronic weight management. We sought to characterize the exposure-response relationship for weight reduction in patients with overweig…
Jastreboff AM, Aronne LJ, Ahmad NN,Tirzepatide Once Weekly for the Treatment of Obesity.2022;387:205-216.
Recent advancements in pharmacologic treatment of obesity and metabolic disease with nutrient-stimulated hormones (NuSH), particularly Semaglutide and Tirzepatide, have been revolutionary, showing weight reduction results comparable to some surgical…
OBJECTIVE: To evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on alcohol-related outcomes in adults with or without alcohol use disorder (AUD). METHODS: A systematic review and meta-analysis following PRISMA guidelines se…
BACKGROUND: Obesity is a complex disease marked by excessive, dysfunctional adipose tissue accumulation. Recent research underscores the pivotal role of brown adipose tissue (BAT) in metabolic health and its potential as a therapeutic target for obes…
Leptin resistance limits anti-obesity efficacy. We identified a leptin-sensitizing mechanism through tirzepatide (TZP), a glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonist. Our tir…
INTRODUCTION: Individuals with spinal cord injury (SCI) experience alterations in metabolism that result in increased central obesity, insulin resistance, and dyslipidemia placing them at elevated risk for developing cardiometabolic disease (CMD). In…
To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in subjects with type 2 diabetes (T2DM). Electronic databases were searched from inception to 2nd October 2024 for randomised controlled trials comparing GLP-1RAs…
INTRODCUTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the most effective treatments for type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic receptors, improving glycemia by boosting insulin secretion while decreasi…
AIM: To evaluate the long-term efficacy and safety data at 104 weeks in tirzepatide-treated participants with type 2 diabetes who had inadequate glycaemic control on metformin and/or sulfonylurea. MATERIALS AND METHODS: This post-hoc analysis was bas…
: With rising obesity rates, pharmacological interventions are increasingly used in non-diabetic adults. While being effective in managing weight, these agents frequently cause gastrointestinal (GI) side effects, affecting adherence and long-term out…